Fei‐Ting Hsu

2.7k total citations
120 papers, 2.1k citations indexed

About

Fei‐Ting Hsu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Fei‐Ting Hsu has authored 120 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Molecular Biology, 32 papers in Cancer Research and 29 papers in Oncology. Recurrent topics in Fei‐Ting Hsu's work include Magnolia and Illicium research (19 papers), Cancer, Stress, Anesthesia, and Immune Response (17 papers) and Biological Activity of Diterpenoids and Biflavonoids (15 papers). Fei‐Ting Hsu is often cited by papers focused on Magnolia and Illicium research (19 papers), Cancer, Stress, Anesthesia, and Immune Response (17 papers) and Biological Activity of Diterpenoids and Biflavonoids (15 papers). Fei‐Ting Hsu collaborates with scholars based in Taiwan, United States and South Korea. Fei‐Ting Hsu's co-authors include I‐Tsang Chiang, Yu‐Chang Liu, Jing‐Gung Chung, Jeng‐Jong Hwang, Po–Jung Pan, Cheng‐Yu Chen, Jiann‐Hwa Chen, SONG-SHEI LIN, Ping‐Huei Tsai and Yu‐Chieh Jill Kao and has published in prestigious journals such as ACS Nano, Cancer Research and Scientific Reports.

In The Last Decade

Fei‐Ting Hsu

116 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fei‐Ting Hsu Taiwan 27 1.0k 415 385 306 250 120 2.1k
Jeng‐Jong Hwang Taiwan 26 771 0.8× 384 0.9× 268 0.7× 284 0.9× 345 1.4× 81 1.7k
HyeSook Youn South Korea 30 1.4k 1.4× 725 1.7× 469 1.2× 331 1.1× 178 0.7× 70 2.4k
Hua You China 23 605 0.6× 282 0.7× 313 0.8× 233 0.8× 64 0.3× 70 1.5k
Hua Guo United States 24 1.3k 1.2× 315 0.8× 840 2.2× 273 0.9× 383 1.5× 69 2.3k
Adriano Angelucci Italy 36 1.7k 1.6× 674 1.6× 962 2.5× 609 2.0× 163 0.7× 106 3.3k
Kai Zhao China 23 748 0.7× 360 0.9× 220 0.6× 147 0.5× 73 0.3× 107 1.6k
Katiuscia Dallaglio Italy 21 1.0k 1.0× 395 1.0× 644 1.7× 132 0.4× 56 0.2× 31 1.8k

Countries citing papers authored by Fei‐Ting Hsu

Since Specialization
Citations

This map shows the geographic impact of Fei‐Ting Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei‐Ting Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei‐Ting Hsu more than expected).

Fields of papers citing papers by Fei‐Ting Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fei‐Ting Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei‐Ting Hsu. The network helps show where Fei‐Ting Hsu may publish in the future.

Co-authorship network of co-authors of Fei‐Ting Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Fei‐Ting Hsu. A scholar is included among the top collaborators of Fei‐Ting Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fei‐Ting Hsu. Fei‐Ting Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Yu‐Chang, et al.. (2025). Magnolol as a Radiotherapy Enhancer in Oral Squamous Cell Carcinoma: Targeting the EGFR/NF‐κB Pathway and Immune Modulation. Journal of Cellular and Molecular Medicine. 29(16). e70699–e70699.
2.
Hsu, Fei‐Ting, et al.. (2024). Atrophy of the cholinergic regions advances from early to late mild cognitive impairment. Neuroradiology. 66(4). 543–556. 2 indexed citations
3.
Hsu, Fei‐Ting, et al.. (2023). Accessing Apoptosis Induction and Metastasis Inhibition Effect of Magnolol on Triple Negative Breast CancerIn Vitro. In Vivo. 37(3). 1028–1036. 5 indexed citations
4.
Hsu, Fei‐Ting, et al.. (2023). Fluoxetine inactivates STAT3/NF-κB signaling and promotes sensitivity to cisplatin in bladder cancer. Biomedicine & Pharmacotherapy. 164. 114962–114962. 9 indexed citations
5.
Liu, Yu‐Chang, et al.. (2023). Inactivation of EGFR/ERK/NF‐κB signalling associates with radiosensitizing effect of 18β‐glycyrrhetinic acid on progression of hepatocellular carcinoma. Journal of Cellular and Molecular Medicine. 27(11). 1539–1549. 11 indexed citations
6.
7.
8.
Wang, Wei‐Shu, et al.. (2022). DNA damage and NF‐κB inactivation implicate glycyrrhizic acid‐induced G 1 phase arrest in hepatocellular carcinoma cells. Journal of Food Biochemistry. 46(7). e14128–e14128. 13 indexed citations
9.
Chiang, I‐Tsang, Yu‐Chang Liu, Huashan Liu, et al.. (2022). Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma. Neurotherapeutics. 19(2). 616–634. 19 indexed citations
10.
Weng, Yueh‐Shan, et al.. (2022). Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial–Mesenchymal Transition and Metastasis. International Journal of Radiation Oncology*Biology*Physics. 115(3). 719–732. 19 indexed citations
11.
Hsu, Fei‐Ting, et al.. (2020). Hyperforin induces apoptosis through extrinsic/intrinsic pathways and inhibits EGFR/ERK/NF‐κB‐mediated anti‐apoptotic potential in glioblastoma. Environmental Toxicology. 35(10). 1058–1069. 16 indexed citations
12.
13.
Hsu, Fei‐Ting, et al.. (2020). Induction of apoptosis through extrinsic/intrinsic pathways and suppression of ERK/NF‐κB signalling participate in anti‐glioblastoma of imipramine. Journal of Cellular and Molecular Medicine. 24(7). 3982–4000. 32 indexed citations
14.
Pan, Po–Jung, Yu‐Chang Liu, & Fei‐Ting Hsu. (2019). Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo. Journal of Clinical Medicine. 8(6). 900–900. 31 indexed citations
15.
Chen, Jiann‐Hwa, et al.. (2019). Apoptosis induction and ERK/NF‐κB inactivation are associated with magnolol‐inhibited tumor progression in hepatocellular carcinoma in vivo. Environmental Toxicology. 35(2). 167–175. 30 indexed citations
16.
Chung, Jing‐Gung, et al.. (2019). Regorefenib induces extrinsic/intrinsic apoptosis and inhibits MAPK/NF‐κB‐modulated tumor progression in bladder cancer in vitro and in vivo. Environmental Toxicology. 34(6). 679–688. 29 indexed citations
17.
Chen, Jiann‐Hwa, I‐Tsang Chiang, & Fei‐Ting Hsu. (2019). Protein Kinase B Inactivation Is Associated with Magnolol-Enhanced Therapeutic Efficacy of Sorafenib in Hepatocellular Carcinoma In Vitro and In Vivo. Cancers. 12(1). 87–87. 16 indexed citations
18.
Lu, Chia‐Feng, Fei‐Ting Hsu, Kevin Li‐Chun Hsieh, et al.. (2018). Machine Learning–Based Radiomics for Molecular Subtyping of Gliomas. Clinical Cancer Research. 24(18). 4429–4436. 210 indexed citations
19.
Lin, Ching‐Yu, Shun‐Tai Yang, Shing‐Chuan Shen, et al.. (2018). Serum amyloid A1 in combination with integrin αVβ3 increases glioblastoma cells mobility and progression. Molecular Oncology. 12(5). 756–771. 27 indexed citations
20.
Hsu, Fei‐Ting, et al.. (2018). MRI tracking of polyethylene glycol-coated superparamagnetic iron oxide-labelled placenta-derived mesenchymal stem cells toward glioblastoma stem-like cells in a mouse model. Artificial Cells Nanomedicine and Biotechnology. 46(sup3). 448–459. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeng‐Jong Hwang Breakdown of academic impact, for papers by HyeSook Youn Breakdown of academic impact, for papers by Hua You Breakdown of academic impact, for papers by Hua Guo Breakdown of academic impact, for papers by Adriano Angelucci Breakdown of academic impact, for papers by Kai Zhao Breakdown of academic impact, for papers by Katiuscia Dallaglio
Rankless by CCL
2026